Trial Profile

A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary)
Indications Advanced breast cancer; Bone metastases; Multiple myeloma; Prostate cancer
Focus Adverse reactions
Sponsors Bayer; Bayer HealthCare

Most Recent Events

15 May 2024 This trial has been completed in Spain (End date: 2024-01-31), According to European Clinical Trials Database record.
30 Apr 2024 This trial has been completed in Belgium (End date: 2024-01-31), According to European Clinical Trials Database record.
08 Mar 2024 This trial has been completed in Germany, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com